{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-012762","form_type":"8-K","ticker":"MRAI","cik":"0001844392","company_name":"Marpai, Inc.","filed_at":"2024-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.941987+00:00","generated_at":"2026-06-06T05:50:52.431832+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Marpai secures $1.7M revenue-based financing; amends AXA purchase deal to potentially reduce $3M obligation","bullets":["Entered Libertas revenue-based financing: sold $2.193M future receipts for $1.7M; weekly payments over 9 months.","AXA amendment reduces 2024 payment to $473,688 and defers further payments to 2025.","Potential $3M reduction in AXA purchase price if CEO invests $3M equity, Nasdaq listing maintained, and payments made.","CEO Damien Lamendola guarantees Libertas funding; also commits to $3M equity investment in 2024.","Company expects to use Libertas proceeds for short-term working capital needs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-012762","json":"https://secwatch.observer/filing/0000950170-24-012762.json","markdown":"https://secwatch.observer/filing/0000950170-24-012762.md","text":"https://secwatch.observer/filing/0000950170-24-012762.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1844392/000095017024012762/0000950170-24-012762-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1844392/000095017024012762/mrai-20240205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T05:50:52.431832+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"116bf5912b2b538ebdc623cb8af49c84df092a05","claim":"Marpai, Inc. amended Amendment No. 1 to Purchase Agreement with AXA S.A. (effective 2024-02-07).","evidence_excerpt":"On February 7, 2024, Marpai, Inc. (the “Company”) entered into Amendment No. 1 to Purchase Agreement (the “AXA Amendment”) with AXA S.A., a French société anonyme (“AXA”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1844392/000095017024012762/0000950170-24-012762-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"AXA S.A."},{"label":"Effective","value":"2024-02-07"}],"fact_type":"material_agreement"},{"claim_id":"75abf6bb4b1c7cc73e0e4c39f32b5ae49d9f0421","claim":"Marpai, Inc. entered into Agreement of Sale of Future Receipts with Libertas Funding LLC valued at $2,193,000 (effective 2024-02-05).","evidence_excerpt":"On February 5, 2024, the Company entered into an Agreement of Sale of Future Receipts (the “Libertas Agreement”) with Libertas Funding LLC (“Libertas”) to sell future receipts totaling $2,193,000 for a purchase price of $1,700,000.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1844392/000095017024012762/0000950170-24-012762-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Libertas Funding LLC"},{"label":"Value","value":"$2,193,000"},{"label":"Effective","value":"2024-02-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}